1. Home/
  2. Compounds/
  3. tanespimycin:bortezomib (250:1 mol/mol)

tanespimycin:bortezomib (250:1 mol/mol)


SourcesNames Used
CTRPv2tanespimycin:bortezomib (250:1 mol/mol)
PharmacoGx tanespimycin:bortezomib (250:1 mol/mol)

Cell lines tested with tanespimycin:bortezomib (250:1 mol/mol)

797 cell lines have been tested with this compound, using data from 1 dataset(s).
CAL-29 urinary tract CTRPv21
CAL-120 breast CTRPv21
BFTC-909 urinary tract CTRPv21
253J-BV urinary tract CTRPv21
MKN1 stomach CTRPv21
KPL-1 breast CTRPv21
CAS-1 central nervous system CTRPv21
Download CSV

Tissues tested with tanespimycin:bortezomib (250:1 mol/mol)

25 tissues have been tested with this compound, using data from 1 dataset(s).
haematopoietic and lymphoid tissueCTRPv2135
central nervous systemCTRPv245
large intestineCTRPv239
Download CSV
Download Data as CSV

Top molecular features associated with response to tanespimycin:bortezomib (250:1 mol/mol)

Feature TypeStandardized
Nominal ANOVA
mRNA TMED6 CTRPv2 AAC -2e-05 1
mRNA ELL2 CTRPv2 AAC 1.8e-05 1
mRNA ARL6IP1 CTRPv2 AAC 1.2e-05 1
mRNA GRM3 CTRPv2 AAC -9.2e-06 1
mRNA ACTL9 CTRPv2 AAC 8.7e-06 1
mRNA VPS25 CTRPv2 AAC 8.7e-06 1
mRNA USP50 CTRPv2 AAC 7e-06 1
mRNA CACUL1 CTRPv2 AAC 3.3e-06 1
mRNA OR2B6 CTRPv2 AAC -2.4e-06 1
mRNA TMEM45A CTRPv2 AAC -2.5e-06 1
Download CSV